Head to Head Comparison of Suppression of Tumorogenicity 2 and Copeptin Significance for Prognosis of Patients After Acute Heart Failure Decompensation

Kardiologiia. 2018 Nov 17;57(9):20-33. doi: 10.18087/cardio.2017.9.10028.

Abstract

Purpose: To assess the suppression of tumorogenicity 2 (ST2) and copeptin significance for risk stratification of patient (pts) with acute decompensated heart failure (ADHF) during long-term follow-up compared with traditional risk factors.

Methods: We included in a prospective study 159 pts with ADHF. Blood samples to determine copeptin, sST2, NT-proBNP and hsTnT concentration were collected at admission and at discharge from the hospital. Serial determination of biomarker concentration was performed at 3, 6 and 12 months of follow-up. The combined primary end point of the trial included cardiovascular (CV) death, hospitalization due to HF, episodes of HF deterioration requiring additional intravenous diuretics and CV death with successful resuscitation.

Results: During 1-year follow-up (295.3±113.2 days) 56 pts (35.2%) had 78 (49.1%) cardiovascular events. Biomarker concentrations in low risk pts (without CV events) were significantly lower compared with high risk pts (with CV events). Discharge copeptin and NT-proBNP values were comparable for pts risk stratification: AUC=0.727 (95% CI 0.637-0.816), р.

Publication types

  • Comparative Study

MeSH terms

  • Biomarkers
  • Glycopeptides
  • Heart Failure*
  • Humans
  • Natriuretic Peptide, Brain
  • Prognosis
  • Prospective Studies

Substances

  • Biomarkers
  • Glycopeptides
  • copeptins
  • Natriuretic Peptide, Brain